Case Report: Ensartinib as a first-line treatment for SMARCA4-deficient and EML4-ALK non-small cell lung cancer
SMARC4 is the catalytic subunit of the SWI/SNF chromatin remodeling complex and is one of the most common altered chromatin remodeling ATPases in cancer. Studies have indicated that SMARCA4 loss is associated with highly aggressive tumors, independently predicting shorter overall and disease-specifi...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1530142/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849323747047112704 |
|---|---|
| author | Yanqing Pan Lingxin Yan Shaoxi Wang Huiling Li Quanfang Chen |
| author_facet | Yanqing Pan Lingxin Yan Shaoxi Wang Huiling Li Quanfang Chen |
| author_sort | Yanqing Pan |
| collection | DOAJ |
| description | SMARC4 is the catalytic subunit of the SWI/SNF chromatin remodeling complex and is one of the most common altered chromatin remodeling ATPases in cancer. Studies have indicated that SMARCA4 loss is associated with highly aggressive tumors, independently predicting shorter overall and disease-specific survival. SMARCA4-deficient non-small cell lung cancer (NSCLC) primarily affects male individuals, especially smokers, and is characterized by large, aggressive tumors. Cases of SMARCA4 deletion combined with actionable driver gene mutations (e.g., ALK) are rarely reported. In this report, we describe a male non-smoker diagnosed with SMARCA4-deficient, EML4-ALK non-small cell lung cancer who has been undergoing ensartinib targeted therapy for 3 months, resulting in a significant partial response. We also propose that, from a signaling perspective, the presence of SMARCA4 deficiency may influence the sensitivity of EML4-ALK NSCLC to targeted therapy, highlighting the need for further investigation into the underlying mechanisms and the exploration of novel therapeutic approaches. |
| format | Article |
| id | doaj-art-8be2af2b366a497f945fec949b513887 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-8be2af2b366a497f945fec949b5138872025-08-20T03:48:57ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-05-011510.3389/fonc.2025.15301421530142Case Report: Ensartinib as a first-line treatment for SMARCA4-deficient and EML4-ALK non-small cell lung cancerYanqing Pan0Lingxin Yan1Shaoxi Wang2Huiling Li3Quanfang Chen4Department of Respiratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, ChinaDepartment of Respiratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, ChinaDepartment of Respiratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, ChinaDepartment of Respiratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, ChinaDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, ChinaSMARC4 is the catalytic subunit of the SWI/SNF chromatin remodeling complex and is one of the most common altered chromatin remodeling ATPases in cancer. Studies have indicated that SMARCA4 loss is associated with highly aggressive tumors, independently predicting shorter overall and disease-specific survival. SMARCA4-deficient non-small cell lung cancer (NSCLC) primarily affects male individuals, especially smokers, and is characterized by large, aggressive tumors. Cases of SMARCA4 deletion combined with actionable driver gene mutations (e.g., ALK) are rarely reported. In this report, we describe a male non-smoker diagnosed with SMARCA4-deficient, EML4-ALK non-small cell lung cancer who has been undergoing ensartinib targeted therapy for 3 months, resulting in a significant partial response. We also propose that, from a signaling perspective, the presence of SMARCA4 deficiency may influence the sensitivity of EML4-ALK NSCLC to targeted therapy, highlighting the need for further investigation into the underlying mechanisms and the exploration of novel therapeutic approaches.https://www.frontiersin.org/articles/10.3389/fonc.2025.1530142/fullcase reportensartinibSMARCA4-deficientEML4-ALKnon-small cell lung cancer |
| spellingShingle | Yanqing Pan Lingxin Yan Shaoxi Wang Huiling Li Quanfang Chen Case Report: Ensartinib as a first-line treatment for SMARCA4-deficient and EML4-ALK non-small cell lung cancer Frontiers in Oncology case report ensartinib SMARCA4-deficient EML4-ALK non-small cell lung cancer |
| title | Case Report: Ensartinib as a first-line treatment for SMARCA4-deficient and EML4-ALK non-small cell lung cancer |
| title_full | Case Report: Ensartinib as a first-line treatment for SMARCA4-deficient and EML4-ALK non-small cell lung cancer |
| title_fullStr | Case Report: Ensartinib as a first-line treatment for SMARCA4-deficient and EML4-ALK non-small cell lung cancer |
| title_full_unstemmed | Case Report: Ensartinib as a first-line treatment for SMARCA4-deficient and EML4-ALK non-small cell lung cancer |
| title_short | Case Report: Ensartinib as a first-line treatment for SMARCA4-deficient and EML4-ALK non-small cell lung cancer |
| title_sort | case report ensartinib as a first line treatment for smarca4 deficient and eml4 alk non small cell lung cancer |
| topic | case report ensartinib SMARCA4-deficient EML4-ALK non-small cell lung cancer |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1530142/full |
| work_keys_str_mv | AT yanqingpan casereportensartinibasafirstlinetreatmentforsmarca4deficientandeml4alknonsmallcelllungcancer AT lingxinyan casereportensartinibasafirstlinetreatmentforsmarca4deficientandeml4alknonsmallcelllungcancer AT shaoxiwang casereportensartinibasafirstlinetreatmentforsmarca4deficientandeml4alknonsmallcelllungcancer AT huilingli casereportensartinibasafirstlinetreatmentforsmarca4deficientandeml4alknonsmallcelllungcancer AT quanfangchen casereportensartinibasafirstlinetreatmentforsmarca4deficientandeml4alknonsmallcelllungcancer |